- Stocks
- Healthcare
- NASDAQ: OMGA

Price (delayed)

$1.93

Market cap

$106.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$173.69M

The company's gross profit has surged by 113% YoY and by 60% QoQ

The revenue has soared by 113% year-on-year and by 60% since the previous quarter

Omega Therapeutics's quick ratio has plunged by 67% YoY and by 16% from the previous quarter

The equity has dropped by 66% year-on-year and by 29% since the previous quarter

What are the main financial stats of OMGA

Market
Valuations
Earnings

Shares outstanding

55.15M

Market cap

$106.45M

Enterprise value

$173.69M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.57

Price to sales (P/S)

21.55

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

35.17

Revenue

$4.94M

EBIT

-$91.6M

EBITDA

-$84.32M

Free cash flow

-$77.96M

Per share
Balance sheet
Liquidity

EPS

-$1.66

Free cash flow per share

-$1.41

Book value per share

$0.75

Revenue per share

$0.09

TBVPS

$3.33

Total assets

$183.68M

Total liabilities

$142.33M

Debt

$127.62M

Equity

$41.35M

Working capital

$46.21M

Debt to equity

3.09

Current ratio

2.87

Quick ratio

2.49

Net debt/EBITDA

-0.8

Margins
Efficiency
Dividend

EBITDA margin

-1,707.1%

Gross margin

100%

Net margin

-1,868.4%

Operating margin

-1,921.3%

Return on assets

-44.2%

Return on equity

-136%

Return on invested capital

-40.2%

Return on capital employed

-57.6%

Return on sales

-1,854.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Omega Therapeutics stock price performed over time

Intraday

4.32%

1 week

-7.66%

1 month

-20.58%

1 year

-63.45%

YTD

-35.88%

QTD

-6.76%

How have Omega Therapeutics's revenue and profit performed over time

Revenue

$4.94M

Gross profit

$4.94M

Operating income

-$94.89M

Net income

-$92.28M

Gross margin

100%

Net margin

-1,868.4%

The company's gross profit has surged by 113% YoY and by 60% QoQ

The revenue has soared by 113% year-on-year and by 60% since the previous quarter

The net margin has surged by 60% year-on-year and by 41% since the previous quarter

The company's operating margin has surged by 59% YoY and by 41% QoQ

What is Omega Therapeutics's growth rate over time

What is Omega Therapeutics stock price valuation

P/E

N/A

P/B

2.57

P/S

21.55

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

35.17

The EPS has grown by 25% YoY and by 8% from the previous quarter

The equity has dropped by 66% year-on-year and by 29% since the previous quarter

The stock's price to book (P/B) is 17% less than its last 4 quarters average of 3.1

The revenue has soared by 113% year-on-year and by 60% since the previous quarter

The price to sales (P/S) is 66% less than the last 4 quarters average of 63.4

How efficient is Omega Therapeutics business performance

The ROIC has soared by 68% YoY and by 24% from the previous quarter

OMGA's ROE has plunged by 64% YoY and by 23% from the previous quarter

The ROS has soared by 60% YoY and by 41% from the previous quarter

OMGA's return on assets is up by 32% year-on-year and by 8% since the previous quarter

What is OMGA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for OMGA.

How did Omega Therapeutics financials performed over time

The total assets is 29% greater than the total liabilities

Omega Therapeutics's quick ratio has plunged by 67% YoY and by 16% from the previous quarter

Omega Therapeutics's current ratio has plunged by 65% YoY and by 14% from the previous quarter

The equity has dropped by 66% year-on-year and by 29% since the previous quarter

OMGA's debt to equity is up by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.